Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5284569 | 0.83 | ADORA2A (0.32) | MEN1KMT2A | |
| SCHEMBL5283796 | 0.80 | ALDH1A1 (0.38) | MEN1KMT2A | |
| SCHEMBL22792081 | 0.75 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL22951354 | 0.73 | GRIN2B (0.37) | MEN1KMT2A | |
| SCHEMBL22951450 | 0.69 | — | — | |
| SCHEMBL25153648 | 0.68 | — | — | |
| SCHEMBL2881981 | 0.68 | — | — | |
| SCHEMBL5275734 | 0.68 | — | — | |
| SCHEMBL16401247 | 0.68 | — | — | |
| SCHEMBL15867581 | 0.68 | CYP1A2 (0.41) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-07-12 | — | — | US | disclosed |
| US-9902721-B2 | N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902721-B2 | N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9873705-B2 | Vinylogous thioester compounds and methods of use | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873705-B2 | Vinylogous thioester compounds and methods of use | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170152262-A1 | VINYLOGOUS THIOESTER COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-01 | — | — | US | disclosed |
| US-20170152262-A1 | VINYLOGOUS THIOESTER COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-01 | — | — | US | disclosed |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| EP-1859781-A2 | Brightening and/or colouring agent with triazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | LRRK2 58/4885MEN1 2334/4885KMT2A 3677/4885 |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | BUB1, BUB1B, CDK1 | LRRK2 587/4885MEN1 478/4885KMT2A 3125/4885 |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | BUB1, BUB1B, CDK1 | LRRK2 587/4885MEN1 478/4885KMT2A 3125/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | LRRK2 3909/4885MEN1 4867/4885KMT2A 2576/4885 |
| US-20170152262-A1 | VINYLOGOUS THIOESTER COMPOUNDS AND METHODS OF USE | ACOT7, LYPLA2, PPT1 | LRRK2 1219/4885MEN1 2790/4885KMT2A 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.